Gene and cell therapy product sponsors should have a plan for ensuring that long-term safety follow-up is completed even if they go out of business, the US Food and Drug Administration said.
Two final guidance documents released on 29 January, “Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products” and “Human Gene Therapy Products Incorporating Human Genome Editing,”
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?